LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Elenco Azioni・Novartis AG

Novartis AG

Chiusa

150.46 0.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

150

Massimo

151.62

Metriche Chiave
By Trading Economics
Entrata	747M 3.2B
Vendite	189M 14B
P/E Media del settore	21.368 49.701
EPS	1.65
Rendimento da dividendi	3.18
Margine di Profitto	23.336
Dipendenti	75,267
EBITDA	338M 5.4B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+11.05% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	3.18% 2.39%

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	6.3B 285B
Apertura precedente	150.4
Chiusura precedente	150.46

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 112.63 Supporto e resistenza

Novartis AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 apr 2026, 09:05 UTC

Utili

Novartis Earnings Hit by Generic Competition -- Update

28 apr 2026, 05:51 UTC

Utili

Novartis Could Upgrade Future Growth Outlook

27 mar 2026, 10:24 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mar 2026, 06:36 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 apr 2026, 09:18 UTC

Discorsi di Mercato

Utili

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 apr 2026, 07:26 UTC

Discorsi di Mercato

Utili

Novartis's Results Are Mixed -- Market Talk

28 apr 2026, 05:07 UTC

Utili

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 apr 2026, 05:05 UTC

Utili

Novartis: On Track to Deliver Full-Year Guiance

28 apr 2026, 05:04 UTC

Utili

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 apr 2026, 05:04 UTC

Utili

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 apr 2026, 05:03 UTC

Utili

Novartis 1Q Core EPS $1.99

28 apr 2026, 05:03 UTC

Utili

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 apr 2026, 05:02 UTC

Utili

Novartis 1Q Core Operating Profit $4.90B

28 apr 2026, 05:02 UTC

Utili

Analysts Saw Novartis 1Q Sales at $13.34B

28 apr 2026, 05:01 UTC

Utili

Novartis 1Q Sales $13.11B

28 apr 2026, 05:00 UTC

Utili

Novartis Backs 2026 View

28 apr 2026, 05:00 UTC

Utili

Novartis AG 1Q EPS $1.65

28 apr 2026, 05:00 UTC

Utili

Novartis AG 1Q Net Pft $3.2B

28 apr 2026, 05:00 UTC

Utili

Novartis AG 1Q Adj EPS $1.99

24 apr 2026, 05:20 UTC

Utili

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 apr 2026, 05:19 UTC

Utili

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 apr 2026, 05:19 UTC

Utili

Novartis: Prequalification Is a Process Run by the WHO

10 apr 2026, 11:45 UTC

Discorsi di Mercato

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 apr 2026, 08:01 UTC

Discorsi di Mercato

Novartis Likely to Confirm Guidance -- Market Talk

30 mar 2026, 09:37 UTC

Discorsi di Mercato

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mar 2026, 07:54 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mar 2026, 06:22 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mar 2026, 06:05 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mar 2026, 06:04 UTC

Acquisizioni, Fusioni, Takeovers

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mar 2026, 06:03 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Confronto tra pari

Modifica del prezzo

Novartis AG Previsione

Obiettivo di Prezzo

By TipRanks

11.05% in crescita

Previsioni per 12 mesi

Media 167.07 USD 11.05%

Alto 180 USD

Basso 141 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novartis AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Novartis AG - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 112.63Supporto e resistenza

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.